



**REF:LNOC/OMR:040010**

Maseru, April 2025

Ms Mokulebete MAKATISI  
Maseru

---

**(INCORPORATING THE NATIONAL ANTI-DOPING ORGANIZATION-NADO)  
VS  
MS MOKULUBETE BLANDINA MAKATISI (“THE ATHLETE”)  
IN RESPECT OF THE ANTI-DOPING RULE VIOLATION (ADVERSE ANALYTICAL  
FINDING)**

---

**Introduction**

1. This is a reasoned decision in accordance with Article 8.3.3 of the Lesotho National Anti-Doping Rules. To the extent not defined herein technical terms shall have the meanings given to in the latest version of the World Anti-Doping Code.
2. The reasoned decision finds that the Athlete has committed an Anti-Doping Rule Violation (“an ADRV”) and sets out the consequences imposed by the Lesotho National Olympic Committee (LNOC) as the NADO for the Kingdom of Lesotho.

**Parties**

3. The LNOC is the governing body of the Olympic Movement which also incorporates the Commonwealth Games Association (CGA) for the Kingdom of Lesotho. Furthermore, in the absence of a legally constituted National Anti-Doping Organization (NADO), the LNOC is mandated by the World Anti-Doping Code and Olympic Charter to act as the *de facto* NADO for the Kingdom of Lesotho.
4. The Athlete participating and competing in Long Distance Athletics is a citizen of the Kingdom of Lesotho.

## Background

5. This matter is considered according to the Lesotho National Anti-Doping Rules as read with the World Anti-Doping Code (2021).
6. On 11 October 2024, a Doping Control Officer (“DCO”) collected a Urine Sample from you in an Out-of-Competition (OOC) test, with Sample Code numbers A1010499 (the “A Sample”) and B 1010499 (the “B Sample”).
7. The Athlete signed the Doping Control Form (DCF). By doing so, the Athlete indicated that she was satisfied with the sample collection procedures that had been followed in conducting the sample collection. The Athlete did not declare any medication or supplements that she had consumed in the relevant section on the Doping Control Form.
8. The A and B Sample were transported to the World Anti-Doping Agency (“WADA”) -accredited Laboratory in Doha, Qatar, the Anti-Doping Laboratory (the “Laboratory”) for analysis. The Laboratory analysed the A Sample and reported an AAF for the following prohibited substance(s):
  - Epi trenbolone  
S1.1 Anabolic Androgenic Steroids
9. The Africa Zone VI Regional Anti-Doping Organization (RADO), in accordance with Delegation of Responsibilities by the LNOC, conducted an initial review of the AAF which revealed the following:
  - a. The Athlete did not have an applicable Therapeutic Use Exemption (“TUE”) to justify the Presence of Epi trenbolone in your system.
  - b. There is no apparent departure from the International Standard for Testing and Investigations (ISTI) or from the International Standard for Laboratories (ISL) that caused the AAF.
  - c. It is not apparent that the AAF was caused by an ingestion of the Epi trenbolone through an authorized route.
10. On 23 December 2024, the Africa Zone VI RADO notified the Athlete of the AAF via the LNOC in accordance Article 7.2 of the LNOC Anti-Doping Rules (ADR).
11. The AAF Notification advised the Athlete of her rights, including the right to request B Sample Analysis and the laboratory documentation package for the A Sample. The Athlete was informed that if she waived her right to the analysis of the B Sample, she would be deemed to have accepted the accuracy of the A Sample analysis, which, pursuant to Article 2.1.2 ADR constitutes sufficient proof of an ADRV.

12. The AAF Notification specified that the Athlete was required to respond and provide a detailed explanation of the AAF by 10 January 2025.
13. On 07<sup>th</sup> January 2025, the Athlete provided her explanation in response to the AAF Notification (“the Initial Response”)
14. On 09<sup>th</sup> April 2025, the Athlete submitted an Admission of ADRVs and Consequences to the Africa Zone VI RADO Office.
15. In the Admission of ADRVs and Consequences Form, the Athlete confirmed her;
  - a) Admission of committing ADRVs pursuant to Rule 2.1 (Presence of a prohibited Substance or its Metabolites or Markers) and Rule 2.2 (Use of a Prohibited Substance or Prohibited Method) for the presence of Metabolites of;
    - 2.1 Trenbolone which is a Prohibited Substance in S1.1 of the World Anti-Doping Agency (WADA) 2024 Prohibited List.
  - b) Understanding and acceptance of the following consequences for committing the ADRVs:
    - 3.1 *"a period of ineligibility of four (4) years from 11 October 2024 to 10 October 2028"; and*
    - 3.2 *"Disqualification of all competitive results obtained by me since 10 October 2024 with all resulting Consequences".*
  - c) Understanding that if she signed and returned the admission and acceptance of Consequences by **10 April 2025**, the period of Ineligibility referred to above will be reduced by one (1) year to one (1) year from 11 October 2024 to 10 October 2027 and that no further reduction will be allowed under any other Rule and no hearing will be required.

### **Disqualification of Results**

16. Pursuant to Article 9 of the LNOC Anti-Doping Rules, automatic Disqualification of the competitive results obtained by the Athlete since 10 October 2024 including forfeiture of any medal, points and prizes.

### **Resolution without a hearing**

17. The Athlete has admitted the ADRVs asserted against her and has accepted a sanction on the terms specified in accordance with Article 10.8.1 of the LNOC Anti-Doping Rules.

## **Period of Ineligibility**

18. As per the Admission of ADRVs and Consequences referred to in Point 15 above, it is hereby confirmed that the Athlete's period of Ineligibility will run from 11 October 2024 to 10 October 2027.

## **Case Analysis**

19. It is the Athlete's responsibility to ensure that no Prohibited Substance enter their body. It is not necessary that Intent, Fault, Negligence or knowing Use on the part of the Athlete be demonstrated in order to establish an ADRV in line with Article 2.21 or Article 2.2 of the LNOC Anti-Doping Rules.
20. The Athlete is found to have committed ADRVs under Article 2.1 and 2.2 of the LNOC Anti-Doping Rules. It has been established that;
- *Analysis of the Athlete's A Sample returned an AAF for the Prohibited Substance (Epi trenbolone)*
  - *There is a presumption of acceptance of under Article 3.2.2 of the LNOC Anti-Doping Rules that the WADA - accredited laboratory conducted the analysis in line with the WADA ISL;*
  - *The Athlete expressly waived her right to have the B Sample analyzed meaning that the Athlete is deemed to have accepted the accuracy of the A Sample ; and*
  - *The Athlete admitted committing the ADRVs under Articles 2.1 and 2.2 of the LNOC Anti-Doping Rules by signing and returning the Admission of ADRVs and Consequences Form.*

## **Decision**

The Athlete has admitted their commission of ADRVs under Article 2.1 and Article 2.2 of the LNOC Anti-Doping Rules consistent with the presence of a Prohibited Substance in her A Sample.

21. All results obtained by the Athlete from the date of sample provision (10 October 2024) through to the start of the Provisional Suspension (10 January 2025) are hereby disqualified with all resulting Consequences, including the forfeiture of any medals, points and prizes.

## **Appeal**

22. By virtue of her admission of the ADRVs and acceptance of the Consequences as outlined above , the Athlete has waived their right to appeal against or otherwise challenge this decision (both as to the finding that the Athlete has committed and SDRV and as to the imposition of the Consequences set out above in line with Article 13.2 of the LNOC Anti-Doping Rules, save that if such

an appeal is lodged with the Court of Arbitration for Sport (“CAS”) by either WADA or World Athletics (WA), the Athlete will be entitled to exercise their

right of cross appeal in accordance with Article 13.2.4 of the LNOC Anti-Doping Rules.

23. This decision is issued in accordance with the Article 8.33 of the LNOC Anti-Doping Rules.

Yours in Clean Sports,

  
**Morake RALEAKA (Mr.)**  
**Secretary General**



**Cc: Federation of Athletics Lesotho**  
**Africa Zone VI Regional Anti-Doping Organization**